alta-1l: final overall survival results of brigatinib vs crizotinib for alk lung cancer
Published 3 years ago • 583 plays • Length 4:00Download video MP4
Download video MP3
Similar videos
-
2:05
alta-1l: brigatinib vs crizotinib in nsclc
-
1:21
alta-1l: brigatinib vs crizotinib
-
2:09
alta-1l: brigatinib vs crizotinib in alk ansclc
-
5:51
alta-1l: brigatinib vs crizotinib for alk advanced non small cell lung cancer patients
-
6:58
alta-1l: brigatinib versus crizotinib for alk nsclc
-
2:18
alta-1l: brigatinib is superior to crizotinib in alk nsclc
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
5:44
updates in alk lung cancer: glass, alex, alta-1l and crown
-
13:57
慎防無聲殺手！肺癌的預防與治療 - 鄭丹瑞《健康旦》 #呼吸系統科 #林冰醫生 (cc中文字幕)
-
9:00
fda d.i.s.c.o.: two approvals for alk-positive non-small cell lung cancer
-
10:08
efficacy and safety of lorlatinib vs. crizotinib in alk nsclc | dr. sachin gupta | crsf 2023 review
-
3:41
alta-1l updates at esmo 2020: intracranial efficacy and hrqol
-
2:39
why brigatinib was approved to treat alk non-small cell lung cancer?
-
4:38
alta ii: brigatinib in crizotinib-resistant alk nsclc
-
5:28
crown study: lorlatinib vs crizotinib in 1l nsclc
-
0:56
dr. stinchcombe on the alta-1l trial in alk nsclc
-
1:22
dr. campelo on the rationale for the alta-1l trial
-
5:26
asco 2024: lung cancer roundup
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
1:14
dr. rotow on first-line brigatinib versus crizotinib in alk nsclc
-
0:09
brigatinib, original band name: alunbrighope for alk positive non-small cell lung cancer.
-
2:13
alk nsclc: brigatinib indication and alta trial